The National Heart, Lung, and Blood Institute (NHLBI) announced two new funding opportunities for late-stage, single- or multi-site, investigator-initiated clinical trials that address critical questions that fall within the mission of the NHLBI and require non-traditional clinical trial designs with the opportunity for statistical novelty and/or innovation.
The opportunities will support scientific research on rare diseases or therapeutics in which sample-size limitations present challenges for examining the statistical power of traditional randomized clinical trials, precision medicine trials, and late-stage implementation research.
The specific funding opportunities are:
- Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (U34): Applications due October 19, 2017
- Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans Resource Access (X01): Applications due January 12, 2018
Source: National Heart, Lung, and Blood Institute press release, May 18, 2017.